Part I: Biotech Deals: Creating Optimal Licensing and Partnering Arrangements

Please join Arnold & Porter for Part I of our in-person series for legal and business leaders at biotechnology and pharmaceutical companies seeking to optimize their licensing and partnering strategies. In this CLE program, we will explore a question many biotech executives face: “Should you license the asset or partner with another company in development?” Through a live and interactive case study, participants will advise a fictional biotech company weighing three licensing and partnering options.

Arnold & Porter will present key considerations across intellectual property, antitrust, regulatory, pricing, market access, and deal strategy, and then attendees will work through real-world complexities together and present recommendations while navigating unexpected developments.

We will examine key considerations that inform licensing and partnering strategies, including:

• Out-licensing versus strategic alternatives
• Transaction structuring priorities, including diligence focus
• Intellectual property and exclusivity protections
• Regulatory pathway and compliance considerations
• Antitrust and Hart-Scott-Rodino Act compliance issues
• Tariff and pricing dynamics, including IRA and MFN implications
• Coverage, reimbursement, and market access considerations

We look forward to a thoughtful and engaging discussion!